A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer

NCT01130519 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

83

Enrollment

NIH

Sponsor class

Conditions

HLRCC
Sporadic Papillary Renal Cell Cancer

Interventions

DRUG: Bevacizumab
DRUG: Erlotinib

Sponsor

National Cancer Institute (NCI)